LMR Partners’s Biogen BIIB Stock Holding History

LMR Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62.3M	Buy	288,200 +133,900	+87%	+$25.6M	0.23%	89
2026 Q1	$28.3M	Buy	+154,300	New	+$28.4M	0.06%	166
2023 Q4	–	Sell	-72,800	Closed	-$18.7M	–	1003
2023 Q3	$18.7M	Sell	72,800 -156,000	-68%	-$41.7M	0.21%	118
2023 Q2	$65.2M	Buy	+228,800	New	+$68.1M	0.72%	24

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LMR Partners's BIIB Position: Q2 2026 in Review

LMR Partners reduced its Biogen (BIIB) stake by 96% in Q2 2026, selling an estimated $21.3M and leaving 4,866 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1041.

LMR Partners first reported a position in BIIB in Q2 2014 and has held it in 25 quarters since. The position peaked at $49.9M in Q2 2023. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

LMR Partners held 4,866 shares of Biogen worth $1.05M as of Q2 2026.
LMR Partners sold 111,265 Biogen shares in Q2 2026, an estimated $21.3M.
Biogen made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1041 holding.
LMR Partners first reported a position in Biogen in Q2 2014 and has held it in 25 quarters since.
LMR Partners's Biogen position peaked at $49.9M in Q2 2023.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.